• head_banner_01

Low MOQ for Neratinib - Semaglutide for Type 2 Diabetes – Gentolex

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

Our target is to consolidate and improve the quality and service of existing products, meanwhile constantly develop new products to meet different customers' demands for Levetiracetam Powder, N-Boc-3-Pyrrolidinone, 2,6-Diaminopyridine, To significantly improve our service quality, our company imports a large number of foreign advanced devices. Welcome clients from home and abroad to call and inquire!
Low MOQ for Neratinib - Semaglutide for Type 2 Diabetes – Gentolex Detail:

Product Detail

Name  Semaglutide
CAS number  910463-68-2
Molecular formula  C187H291N45O59
Molecular weight  4113.57754
EINECS Number  203-405-2

Synonyms

Sermaglutide; Semaglutide fandachem; Semaglutide impurity; Sermaglutide USP/EP; semaglutide; Sermaglutide CAS 910463 68 2; Ozempic, 

Description

Semaglutide is a new generation of GLP-1 (glucagon-like peptide-1) analogs, and semaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, which has a better effect in the treatment of type 2 diabetes. Novo Nordisk has completed 6 Phase IIIa studies of semaglutide injection, and submitted a new drug registration application for semaglutide weekly injection to the U.S. Food and Drug Administration (FDA) on December 5, 2016. A Marketing Authorization Application (MAA) was also submitted to the European Medicines Agency (EMA).

Compared with liraglutide, semaglutide has a longer aliphatic chain and increased hydrophobicity, but semaglutide is modified with a short chain of PEG, and its hydrophilicity is greatly enhanced. After PEG modification, it can not only bind closely to albumin, cover the enzymatic hydrolysis site of DPP-4, but also reduce renal excretion, prolong the biological half-life, and achieve the effect of long circulation.

Application

Semaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, which is more effective in treating type 2 diabetes.

Bioactivity

Semaglutide (Rybelsus, Ozempic, NN9535, OG217SC, NNC0113-0217) is a long-acting glucagon-like peptide 1 (GLP-1) analog, an agonist of GLP-1receptor, with a potential type 2 Therapeutic efficacy of diabetes mellitus (T2DM).

Quality System

In general, quality system and assurance is in place covering all stage of production of the finished product. Adequate manufacturing and control operations are performed in compliance with the approved procedures/ specifications. Change control and Deviation handling system is in place, and necessary impact assessment and investigation were conducted. Proper procedures are in place to ensure quality of product prior to release into the market.


Product detail pictures:

Low MOQ for Neratinib - Semaglutide for Type 2 Diabetes – Gentolex detail pictures

Low MOQ for Neratinib - Semaglutide for Type 2 Diabetes – Gentolex detail pictures


Related Product Guide:

We thinks what customers think, the urgency of urgency to act during the interests of a purchaser position of theory, allowing for much better good quality, lower processing costs, prices are extra reasonable, won the new and old buyers the support and affirmation for Low MOQ for Neratinib - Semaglutide for Type 2 Diabetes – Gentolex , The product will supply to all over the world, such as: Tajikistan, Guatemala, Egypt, Abiding by our motto of "Hold well the quality and services, Customers Satisfaction", So we provide our clients with high quality products and excellent service. Please feel free to contact us for further information.
  • The quality of the products is very good, especially in the details, can be seen that the company work actively to satisfy customer's interest, a nice supplier.
    5 Stars By Hellyngton Sato from Gambia - 2018.09.19 18:37
    The factory can meet continuously developing economic and market needs, so that their products are widely recognized and trusted, and that's why we chose this company.
    5 Stars By Edith from Grenada - 2018.10.01 14:14
    Write your message here and send it to us